These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21720266)

  • 1. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats.
    Honetschlägerová Z; Sporková A; Kopkan L; Husková Z; Hwang SH; Hammock BD; Imig JD; Kramer HJ; Kujal P; Vernerová Z; Chábová VC; Tesař V; Cervenka L
    J Hypertens; 2011 Aug; 29(8):1590-601. PubMed ID: 21720266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats.
    Erbanová M; Thumová M; Husková Z; Vanecková I; Vanourková Z; Mullins JJ; Kramer HJ; Bürgelová M; Rakusan D; Cervenka L
    J Hypertens; 2009 Mar; 27(3):575-86. PubMed ID: 19330918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats.
    Jíchová Š; Doleželová Š; Kopkan L; Kompanowska-Jezierska E; Sadowski J; Červenka L
    Am J Med Sci; 2016 Dec; 352(6):618-630. PubMed ID: 27916218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
    Honetschlägerová Z; Husková Z; Vaňourková Z; Sporková A; Kramer HJ; Hwang SH; Tsai HJ; Hammock BD; Imig JD; Červenka L; Kopkan L
    J Physiol; 2011 Jan; 589(Pt 1):207-19. PubMed ID: 21078594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.
    Sporková A; Jíchová S; Husková Z; Kopkan L; Nishiyama A; Hwang SH; Hammock BD; Imig JD; Kompanowska-Jezierska E; Sadowski J; Kramer HJ; Cervenka L
    Clin Exp Pharmacol Physiol; 2014 Dec; 41(12):1003-13. PubMed ID: 25224811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system.
    Varcabova S; Huskova Z; Kramer HJ; Hwang SH; Hammock BD; Imig JD; Kitada K; Cervenka L
    Clin Exp Pharmacol Physiol; 2013 Apr; 40(4):273-81. PubMed ID: 23039246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.
    Howard CG; Mullins JJ; Mitchell KD
    Am J Med Sci; 2011 May; 341(5):383-7. PubMed ID: 21358304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME.
    Honetschlägerová Z; Kitada K; Husková Z; Sporková A; Kopkan L; Bürgelová M; Varcabová Š; Nishiyama A; Hwang SH; Hammock BD; Imig JD; Kramer HJ; Kujal P; Vernerová Z; Červenka L
    J Hypertens; 2013 Feb; 31(2):321-32. PubMed ID: 23307303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.
    Jíchová Š; Kopkan L; Husková Z; Doleželová Š; Neckář J; Kujal P; Vernerová Z; Kramer HJ; Sadowski J; Kompanowska-Jezierska E; Reddy RN; Falck JR; Imig JD; Červenka L
    J Hypertens; 2016 Oct; 34(10):2008-25. PubMed ID: 27428043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet.
    Williams DE; Prieto MC; Mullins JJ; Navar LG; Mitchell KD
    Am J Med Sci; 2010 Apr; 339(4):356-61. PubMed ID: 20224314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats.
    Husková Z; Kopkan L; Červenková L; Doleželová Š; Vaňourková Z; Škaroupková P; Nishiyama A; Kompanowska-Jezierska E; Sadowski J; Kramer HJ; Červenka L
    Clin Exp Pharmacol Physiol; 2016 Apr; 43(4):438-49. PubMed ID: 26833491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats.
    Sporková A; Kopkan L; Varcabová S; Husková Z; Hwang SH; Hammock BD; Imig JD; Kramer HJ; Cervenka L
    Am J Physiol Regul Integr Comp Physiol; 2011 Jun; 300(6):R1468-75. PubMed ID: 21411763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats.
    Mitchell KD; Bagatell SJ; Miller CS; Mouton CR; Seth DM; Mullins JJ
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7(2):74-86. PubMed ID: 17083061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension.
    Patterson ME; Mullins JJ; Mitchell KD
    Am J Physiol Renal Physiol; 2008 Jan; 294(1):F205-11. PubMed ID: 17977909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes.
    Mervaala E; Dehmel B; Gross V; Lippoldt A; Bohlender J; Milia AF; Ganten D; Luft FC
    J Am Soc Nephrol; 1999 Aug; 10(8):1669-80. PubMed ID: 10446934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.
    Sedláková L; Kikerlová S; Husková Z; Červenková L; Chábová VČ; Zicha J; Falck JR; Imig JD; Kompanowska-Jezierska E; Sadowski J; Krátký V; Červenka L; Kopkan L
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal nitric oxide synthase and antioxidant preservation in Cyp1a1-Ren-2 transgenic rats with inducible malignant hypertension.
    Cunningham MW; Sasser JM; West CA; Milani CJ; Baylis C; Mitchell KD
    Am J Hypertens; 2013 Oct; 26(10):1242-9. PubMed ID: 23764378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension.
    Vanourková Z; Kramer HJ; Husková Z; Vanecková I; Opocenský M; Chábová VC; Tesar V; Skaroupková P; Thumová M; Dohnalová M; Mullins JJ; Cervenka L
    J Hypertens; 2006 Dec; 24(12):2465-72. PubMed ID: 17082731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
    Červenka L; Melenovský V; Husková Z; Škaroupková P; Nishiyama A; Sadowski J
    Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):795-807. PubMed ID: 25969338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats.
    Howard CG; Mullins JJ; Mitchell KD
    Am J Med Sci; 2010 Jun; 339(6):543-8. PubMed ID: 20375689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.